LINCOLN PHARMACEUTICALS LTD. - 531633 - Regulation 23(9)-Disclosure Of Related Party Transactions
In compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of related party transactions in the specified format for the half year ended March 31, 2022. The same available on the website of the Company at www.lincolnpharma.com LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of newspaper advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and amendments thereof. LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In terms of Regulation 24 (A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time and SEBI Circular No. CIR/CFD/CMDl/27/2019 dated February 08, 2019, we enclosed herewith the annual secretarial compliance report as issued by M/s. Vishwas Sharma & Associates, Practicing Company Secretary (C, P. No. 16942), for the financial year ended on March 31, 2022. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclosed herewith the copies of published newspaper advertisement with respect to the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31, 2022. LINCOLN PHARMACEUTICALS LTD. - 531633 - Financial Result For The Quarter And Year Ended March 31, 2022
board consider audited financial result (standalone & consolidated) for the quarter and year ended March 31, 2022. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board recommends Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2022, inter alia, has recommended a dividend of Rs. 1.50/- (i.e. 15% per share} per equity share of face value of Rs. 10/- for the year ended March 31, 2022, for approval of the members at the ensuring annual general meeting (AGM) of the Company. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting LINCOLN PHARMACEUTICALS LTD. - 531633 - Board to consider Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on May 19, 2022, inter alia, to consider and approve the audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31, 2022 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any.Further, in continuation to the Company''s disclosure on closure of trading window dated March 31, 2022, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2022 and shall reopen after the expiry of 48 hours from the time the result becomesgenerally available.